COVID-19 vaccine shows promising results during clinical trial in Pakistan
Nov 23 2020
An NHS worker from Manchester University NHS Foundation Trust (MFT) has become the first person in the world to be consented into another leading phase 3 COVID-19 vaccine study, testing the safety and effectiveness of a new two-dose vaccine regimen developed by The Janssen Pharmaceutical Companies of Johnson & Johnson.
Days after US-based biotechnology Moderna's vaccine showed 94.5 per cent efficacy in fight against COVID-19 infection, the Company's Chief Executive said that they will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered.
The EU has been in talks with Moderna for its experimental COVID-19 vaccine at least since July.
Sinopharm's chairman told media this week that almost a million people have now received their vaccine for emergency use, though he did not provide a specific figure. Younger participants appeared to experience local and systemic adverse reactions to the vaccines than older participants.
China has been bullish about the development of its vaccine for the new virus, which first emerged in the centre of the country late previous year - with four vaccines now in late-stage testing.
An indigenously developed vaccine by Zydus Cadila has completed phase-two clinical trial in the country.
According to details, the vaccine that is undergoing the third phase of a clinical trial in Pakistan has shown positive results with 95 percent recovery rate of the patients who were about to be shifted on a ventilator.
President Xi Jinping has declared that any Chinese vaccine would be a "global public good", after the country came under criticism, particularly from the United States, for its early handling of the outbreak.
"We have mobilized resources to address the immediate financing needs in global health to support the research, development, manufacturing, and distribution of safe and effective COVID-19 diagnostics, therapeutics and vaccines".